Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFIRINOX and Pembrolizumab in Resectable Pancreatic Cancer
NCT05132504Phase 2Recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Aug 2022
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Baylor College of Medicine. Primary endpoint: Overall Response Rate at 3 years. Started Aug 2022; status: recruiting.
02
Drugs
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05132504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132504.